Free Trial
OTCMKTS:OTLC

Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

Oncotelic Therapeutics logo
$0.01 +0.00 (+1.54%)
As of 11/13/2026 03:15 PM Eastern

About Oncotelic Therapeutics Stock (OTCMKTS:OTLC)

Advanced

Key Stats

Today's Range
$0.0113
▼
$0.0139
50-Day Range
$0.01
▼
$0.03
52-Week Range
$0.01
▼
$0.10
Volume
479,008 shs
Average Volume
460,984 shs
Market Capitalization
$6.03 million
P/E Ratio
0.02
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research includes therapies intended to affect biological pathways involved in tumor growth and the body’s immune response.

The company’s lead candidate, OT-101, is an antisense therapy designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has pursued its development for cancers including glioblastoma and pancreatic cancer; it remains an investigational drug, not an approved treatment.

The company was previously known as Mateon Corporation and adopted the Oncotelic Therapeutics name in 2019. Its leadership includes founder and Chief Executive Officer Dr. Vuong Trieu.

AI Generated. May Contain Errors.

Oncotelic Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

OTLC MarketRank™: 
2.278597785975 of 5 stars

Oncotelic Therapeutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Oncotelic Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncotelic Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.89.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncotelic Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.15.

  • Price to Book Value per Share Ratio

    Oncotelic Therapeutics has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.04% of the float of Oncotelic Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncotelic Therapeutics has recently decreased by 56.72%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oncotelic Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Oncotelic Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Oncotelic Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oncotelic Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncotelic Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    39.22% of the stock of Oncotelic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Oncotelic Therapeutics has minimal institutional ownership at this time.

  • Read more about Oncotelic Therapeutics' insider trading history.
Receive OTLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OTLC Stock News Headlines

Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
OTLC Share News Today
See More Headlines

OTLC Stock Analysis - Frequently Asked Questions

Oncotelic Therapeutics' stock was trading at $0.0775 at the start of the year. Since then, OTLC shares have decreased by 83.0% and is now trading at $0.0132.

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) released its quarterly earnings data on Wednesday, April, 15th. The company reported $0.59 EPS for the quarter.

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:OTLC
CIK
908259
Employees
41
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.59
Trailing P/E Ratio
0.02
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$249.28 million
Net Margins
N/A
Pretax Margin
143,532.39%
Return on Equity
123.75%
Return on Assets
81.36%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
0.08
Quick Ratio
0.08

Sales & Book Value

Annual Sales
$70 thousand
Price / Sales
86.08
Cash Flow
$0.66 per share
Price / Cash Flow
0.02
Book Value
$0.59 per share
Price / Book
0.02

Miscellaneous

Outstanding Shares
456,490,000
Free Float
277,456,000
Market Cap
$6.03 million
Optionable
Not Optionable
Beta
-0.10
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (OTCMKTS:OTLC) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners